Investor Relations

Avantium is a leading technology company in the area of advanced high-throughput R&D with a focus on applications in the energy, chemicals and pharmaceutical industries. Building on our expertise and track record in these industries, we focus on developing products in two fields:

novel biofuels and bio-based chemicals, and
novel crystal forms of marketed drugs under patent.

Our strategy is to progress our development programs and exploit the commercial value of our expanding patent portfolio by securing value-adding partnerships, while at the same time continuing to expand our cash generative services and tools business.

We operate our services and tools activities in two business units: Chemicals, comprising our services and tools for the energy and chemicals industries, and Pharma, comprising our services and tools for the pharmaceutical and biotechnology industries. Our third business unit contains our development programs.

Avantium has a unique international shareholder base. The following venture capital providers support our business:

Aescap Venture (Amsterdam, the Netherlands )

Alpinvest (Amsterdam, the Netherlands)

Capricorn Cleantech Fund (Leuven, Belgium)

DFJ Esprit (London, UK)

EDB Investments (Singapore)

ING Group (Amsterdam, the Netherlands)

Navitas Capital (Bilthoven, the Netherlands)